Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MEDI4736

- PMLiVE

FDA gives Loxo breakthrough tag for second cancer drug

US regulatory body to expect a NDA for LOXO-292 in late 2019

AstraZeneca AZ

AstraZeneca’s Lupus treatment misses mark in trial

Anifrolumab failed to show statistically significant reduction in disease activity

Roche Basel Switzerland

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Deal is latest in series of big pharma investments in cancer immunotherapies

AstraZeneca AZ

AZ rival to GSK’s COPD drug Anoro fails head-to-head test

Its combo missed two of the main endpoints of the study

AstraZeneca AZ

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

Japanese regulator clears the drug for first-line use in NSCLC

- PMLiVE

Roche’s Alecensa backed by China’s National Drug Administration

Approved to treat ALK-positive lung cancer

- PMLiVE

Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?

The next generation of relationship holders will offer highly personalised services

AstraZeneca AZ

New cancer drugs can’t quite plug the revenue hole at AZ

Overall sales fell 5% to $10.33bn

- PMLiVE

Communication is the key to unlocking the potential of immuno-oncology

Communication is a necessity, not an option

- PMLiVE

AZ’s Lynparza closes in on first line ovarian cancer use

Aims for first-line indication in the ovarian cancer setting

SWITCHED ONcology

We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched...

Havas Lynx

18 SWITCHED ONcology: The Big Communication

Matching unprecedented clinical advances in immuno-oncology with transformative communication

Havas Lynx

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links